The who classification of pulmonary hypertension: A case-based imaging compendium

Pulmonary Circulation

Volumn 2, Issue 1, 2012, Pages 107-121

  Ryan, John J ^a   Thenappan, Thenappan ^a   Luo, Nancy ^a   Ha, Thanh ^b   Patel, Amit R ^a   Rich, Stuart ^a   Archer, Stephen L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

CREST; Eisenmenger s syndrome; Late gadolinium enhancement; Pulmonary artery acceleration time; Pulmonary capillary hemangiomatosis; Pulmonary veno occlusive disease; Right ventricular hypertrophy

Indexed keywords

EID: 84867592712     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.94843     Document Type: Article

References (35)

1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250-94.
2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54.
3. Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: Implications for clinical practice. Chest 2011;139:988-93.
4. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
5. Rietema H, Holverda S, Bogaard HJ, Marcus JT, Smit HJ, Westerhof N, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008;31:759-64.
6. Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2011;4:257-65.
7. Elwing J, Panos RJ. Pulmonary hypertension associated with COPD. Int J Chron Obstruct Pulmon Dis 2008;3:55-70.
8. Ryan JJ, Rich S, Archer SL. Pulmonary Endarterectomy Surgery-A Technically Demanding Cure for WHO Group IV Pulmonary Hypertension: Requirements for Centres of Excellence and Availability in Canada. Can J Cardiol 2011;27:671-4.
9. Thistlethwaite PA, Mo M, Madani MM, Deutsch R, Blanchard D, Kapelanski DP, et al. Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J Thorac Cardiovasc Surg 2002;124:1203-11.
10. Al-Naamani K, Hijal T, Nguyen V, Andrew S, Nguyen T, Huynh T. Predictive values of the electrocardiogram in diagnosing pulmonary hypertension. Int J Cardiol 2008;127:214-8.
11. Satoh T, Kyotani S, Okano Y, Nakanishi N, Kunieda T. Descriptive patterns of severe chronic pulmonary hypertension by chest radiography. Respir Med 2005;99:329-36.
12. Isobe M, Yazaki Y, Takaku F, Koizumi K, Hara K, Tsuneyoshi H, et al. Prediction of pulmonary arterial pressure in adults by pulsed Doppler echocardiography. Am J Cardiol 1986;57:316-21.
13. Kitabatake A, Inoue M, Asao M, Masuyama T, Tanouchi J, Morita T, et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation 1983;68:302-9.
14. Urboniene D, Haber I, Fang YH, Thenappan T, Archer SL. Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2010;299:L401-12.
15. Alunni JP, Degano B, Arnaud C, Tétu L, Blot-Soulétie N, Didier A, et al. Cardiac MRI in pulmonary artery hypertension: Correlations between morphological and functional parameters and invasive measurements. Eur Radiol 2010;20:1149-59.
16. Freed B, Gomberg-Maitland M, Chandra S, Mor-Avi V, Rich S, Archer SL, et al. Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. Journal of Cardiovascular Magnetic Resonance 2012, 14:11
17. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 2004;147:218-23.
18. Steinberg I. Calcification of the pulmonary artery and enlargement of the right ventricle: A sign of congenital heart disease. Eisenmenger syndrome- -pulmonary hypertension, increased pulmonary resistance, and reversal of blood flow. Am J Roentgenol Radium Ther Nucl Med 1966;98:369-77.
19. Prasad K, Radhakrishnan S, Sinha N. Extensive calcification of pulmonary arteries with left-to-right shunting across the arterial duct. Int J Cardiol 1992;35:419-21.
20. Bloodworth J, Tomashefski JF Jr. Localised pulmonary metastatic calcification associated with pulmonary artery obstruction. Thorax 1992;47:174-8.
21. Kajita LJ, Martinez EE, Ambrose JA, Lemos PA, Esteves A, Nogueira da Gama M, et al. Extrinsic compression of the left main coronary artery by a dilated pulmonary artery: Clinical, angiographic, and hemodynamic determinants. Catheter Cardiovasc Interv 2001;52:49-54.
22. Rich S, McLaughlin VV, O’Neill W. Stenting to reverse left ventricular ischemia due to left main coronary artery compression in primary pulmonary hypertension. Chest 2001;120:1412-5.
23. Mitsudo K, Fujino T, Matsunaga K, Doi O, Nishihara Y, Awa J, et al. [Coronary arteriographic findings in the patients with atrial septal defect and pulmonary hypertension (ASD + PH)–compression of left main coronary artery by pulmonary trunk]. Kokyu To Junkan 1989;37:649-55.
24. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011;124:164-74.
25. Humbert M, Maitre S, Capron F, Rain B, Musset D, Simonneau G. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998;157:1681-5.
26. Frazier AA, Franks TJ, Mohammed TL, Ozbudak IH, Galvin JR. From the Archives of the AFIP: Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Radiographics 2007;27:867-82.
27. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009;120:1961-8.
28. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004;103:1934-6.
29. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000;95:1229-36.
30. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011;365:44-53.
31. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-95.
32. Dickens C. The Posthumous Papers of the Pickwick Club. London: Chapman & Hall; 1837.
33. Guidry UC, Mendes LA, Evans JC, Levy D, O’Connor GT, Larson MG, et al. Echocardiographic features of the right heart in sleep-disordered breathing: The Framingham Heart Study. Am J Respir Crit Care Med 2001;164: 933-8.
34. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-94.
35. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417-31.